Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

3535 General Atomics Court, Suite 200, San Diego, CA, 92121, USA

Type of Company

Public

Employees (Worldwide)

178

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Fate Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Financial Officer

General Counsel & Secretary

Chief Development Officer

Chief Scientific Officer

Senior Vice President-Corporate Development

Senior Vice President-Technical Operations

Senior Vice President-Clinical Translation

Senior Vice President-Clinical Development

Board of Directors

Former Faculty Member at Harvard University

Founder at Fate Therapeutics, Inc.

Founder at Fate Therapeutics, Inc.

Founding Member at Redmile Group LLC

Former Vice President-Financial Services at California Healthcare Institute

Venture Partner, Life Sciences Team at Frazier Healthcare Partners

Chief Medical Officer at Epizyme, Inc.

Chief Scientific Officer & Executive Vice President-Research at Gritstone Oncology, Inc.

Paths to Fate Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Fate Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Redmill invests in US and non-US healthcare companies. They may also invest in fields related to healthcare where due diligence shows that healthcare assets are the driving force behind value creation and in other sectors from time to time. The firm uses the fundamental research as part of their investment process. Their protocols include company financial models; market models; investment theses; and regular dialogue. Redmill’s sources include contacts with physicians; focus outside US; dialogue with companies; attendance at medical conferences; meetings with private companies; and regular dialogue within the team.

Details Hidden

Johnson & Johnson Innovation JJDC, Inc. is a venture capital arm of Johnson & Johnson (NYSE: JNJ) located in US. The firm targets companies sectors such as pharmaceuticals, medical devices and consumer healthcare services. They provide financing for all stages, from seed-level startups to Series B and beyond.

Details Hidden

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

Recent Transactions
Details Hidden

Fate Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Fate Therapeutics, Inc. issued USD Common Stock

Details Hidden

Fate Therapeutics, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Underwriter

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Underwriter

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Professional

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Advisors & Consultants
Legal Advisor

Chairman, Silicon Valley at Goodwin Procter LLP

Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Consultant

Chief Medical Officer at ORIC Pharmaceuticals, Inc.

Clients

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Key Stats and Financials As of 2019
Market Capitalization
$4.74B
Total Enterprise Value
$1.14B
Earnings Per Share
$-1.44
Revenue
$10.7M
Enterprise Value / Sales
106.74x
TEVNet Income
-11.62x
Debt TEV
0.02x
EBITDAMargin
-922.6%
EBITDA
$-98.5M
Total Debt
$26.9M
Total Equity
$245M
Net Profit
$-98.2M
Three Year Compounded Annual Growth Rate Of Revenue
34.37%
Non-Profit Donations & Grants
Investors
Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

The California Institute for Regenerative Medicine ("The Institute" or "CIRM") was established in early 2005 following the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.

Details Hidden

OVP is an active manager which provides equity financing for seed and early-stage capital requirements. The firm targets companies operating in the technology services and healthcare technology sector, and industries such as information technology services, biotechnology and alternative power generation. OVP initially invests between USD 1 and 5 million in companies located in the United States. The firm looks to take minority positions in its investments.

Suppliers
The Children's Medical Center Corp. Hospitals & Patient Services | Boston, MA

The Children's Medical Center Corp. operates as a non-profit hospital and research center. The company was founded in 1959 and is headquartered in Boston, MA.

The Scripps Research Institute - California Biotechnology | La Jolla, CA

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Whitehead Institute for Biomedical Research Biotechnology | Cambridge, MA

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers. Located in Cambridge, Massachusetts, Whitehead Institute was founded in 1982 by businessman and philanthropist Edwin C. “Jack” Whitehead.

Competitors
CRISPR Therapeutics AG Biotechnology - Zug, Che

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

AbbVie, Inc. Pharmaceuticals - North Chicago, IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fate Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fate Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Fate Therapeutics, Inc..